Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase NA 1Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Breast Neoplasms 1911Neoplasms 1531Prostatic Neoplasms 753Colorectal Neoplasms 714Lung Neoplasms 583Motor Activity 393Head and Neck Neoplasms 328Colonic Neoplasms 312Uterine Cervical Neoplasms 300Pain 248Pancreatic Neoplasms 246Anxiety Disorders 221Rectal Neoplasms 214Carcinoma, Hepatocellular 209Carcinoma, Non-Small-Cell Lung 206Fatigue 194Stomach Neoplasms 192Polycystic Ovary Syndrome 188Ovarian Neoplasms 186Precursor Cell Lymphoblastic Leukemia-Lymphoma 178Brain Neoplasms 169Depression 166Urinary Bladder Neoplasms 165Melanoma 163Neoplasm Metastasis 162Esophageal Neoplasms 140Multiple Myeloma 138Lymphoma 136Lymphoma, Follicular 128Obesity 127

Interventions

Imatinib Mesylate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase NA × Completed × Hypereosinophilic Syndrome × Clear all
NCT00038675 2022-01-04

Therapy of HES, PV, Atypical Chronic Myelocytic Leukemia (CML) or Chronic Myelomonocytic Leukemia (CMML), and Mastocytosis With Imatinib Mesylate

M.D. Anderson Cancer Center

Phase NA Completed
125 enrolled 9 charts
MyeloidOther hematologic neoplasm

Leukemia, Mastocytosis, Polycythemia Vera, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myelomonocytic, Chronic, Hypereosinophilic Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡